 Katja Kiseljak-Vassiliades
Concepts (247)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adrenocortical Carcinoma | 15 | 2025 | 65 | 6.350 |
Why?
| | Adrenal Cortex Neoplasms | 14 | 2025 | 63 | 5.400 |
Why?
| | Adenoma | 6 | 2025 | 230 | 1.600 |
Why?
| | Growth Hormone-Secreting Pituitary Adenoma | 3 | 2017 | 11 | 1.370 |
Why?
| | Pituitary Neoplasms | 9 | 2025 | 190 | 1.360 |
Why?
| | Cadherins | 2 | 2024 | 206 | 1.210 |
Why?
| | Neuroendocrine Tumors | 2 | 2024 | 116 | 0.940 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2025 | 89 | 0.900 |
Why?
| | Adrenal Cortex | 3 | 2020 | 29 | 0.890 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 1 | 2024 | 11 | 0.890 |
Why?
| | Pituitary Gland | 4 | 2018 | 148 | 0.790 |
Why?
| | Dehydroepiandrosterone | 1 | 2022 | 51 | 0.750 |
Why?
| | Gene Expression Regulation, Neoplastic | 11 | 2025 | 1396 | 0.740 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4295 | 0.740 |
Why?
| | Androgens | 1 | 2022 | 187 | 0.680 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2020 | 194 | 0.670 |
Why?
| | Tumor Microenvironment | 4 | 2023 | 674 | 0.660 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2019 | 134 | 0.620 |
Why?
| | Genes, Tumor Suppressor | 3 | 2017 | 86 | 0.620 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2025 | 249 | 0.600 |
Why?
| | Membrane Proteins | 3 | 2025 | 1164 | 0.590 |
Why?
| | Cell Line, Tumor | 13 | 2025 | 3412 | 0.550 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 35 | 0.550 |
Why?
| | Desmosomes | 1 | 2017 | 21 | 0.540 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2025 | 872 | 0.520 |
Why?
| | Receptors, Somatostatin | 1 | 2015 | 25 | 0.490 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 75 | 0.480 |
Why?
| | Acromegaly | 1 | 2014 | 14 | 0.450 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 804 | 0.440 |
Why?
| | Human Growth Hormone | 1 | 2014 | 48 | 0.430 |
Why?
| | Neurosurgical Procedures | 2 | 2018 | 197 | 0.420 |
Why?
| | Antineoplastic Agents | 4 | 2024 | 2129 | 0.410 |
Why?
| | Mitotane | 2 | 2024 | 10 | 0.400 |
Why?
| | Calcium-Binding Proteins | 2 | 2025 | 218 | 0.360 |
Why?
| | Humans | 39 | 2025 | 137585 | 0.330 |
Why?
| | Steroidogenic Factor 1 | 2 | 2025 | 12 | 0.300 |
Why?
| | Apoptosis | 6 | 2021 | 2553 | 0.300 |
Why?
| | Tumor Cells, Cultured | 3 | 2021 | 955 | 0.300 |
Why?
| | Cell Proliferation | 7 | 2023 | 2475 | 0.290 |
Why?
| | Mice, Nude | 2 | 2020 | 698 | 0.290 |
Why?
| | Immunotherapy | 3 | 2025 | 641 | 0.280 |
Why?
| | Genomics | 2 | 2024 | 795 | 0.280 |
Why?
| | Biomarkers, Tumor | 3 | 2021 | 1276 | 0.260 |
Why?
| | Middle Aged | 12 | 2025 | 33479 | 0.260 |
Why?
| | Transcriptome | 3 | 2024 | 971 | 0.260 |
Why?
| | Prognosis | 3 | 2022 | 4030 | 0.240 |
Why?
| | Gene Expression Profiling | 3 | 2024 | 1774 | 0.240 |
Why?
| | Intrinsically Disordered Proteins | 1 | 2025 | 34 | 0.230 |
Why?
| | Nephritis, Interstitial | 1 | 2025 | 14 | 0.230 |
Why?
| | Mice | 10 | 2025 | 17787 | 0.230 |
Why?
| | Amino Acid Transport System y+ | 1 | 2024 | 9 | 0.230 |
Why?
| | Sulfasalazine | 1 | 2024 | 23 | 0.230 |
Why?
| | Drug Repositioning | 1 | 2024 | 35 | 0.220 |
Why?
| | Immunoconjugates | 1 | 2025 | 114 | 0.210 |
Why?
| | Animals | 14 | 2025 | 36940 | 0.210 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2025 | 382 | 0.210 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2024 | 161 | 0.210 |
Why?
| | beta Catenin | 1 | 2025 | 253 | 0.200 |
Why?
| | Adult | 11 | 2025 | 37929 | 0.200 |
Why?
| | Female | 14 | 2025 | 73304 | 0.200 |
Why?
| | Luteinizing Hormone | 1 | 2023 | 185 | 0.190 |
Why?
| | Anorexia | 1 | 2022 | 17 | 0.190 |
Why?
| | Wnt Signaling Pathway | 2 | 2021 | 192 | 0.190 |
Why?
| | Aldosterone | 2 | 2019 | 45 | 0.180 |
Why?
| | Cell Cycle Proteins | 2 | 2018 | 617 | 0.180 |
Why?
| | Hormone Replacement Therapy | 1 | 2022 | 100 | 0.180 |
Why?
| | Aurora Kinase A | 1 | 2021 | 56 | 0.170 |
Why?
| | Retrospective Studies | 6 | 2025 | 15657 | 0.170 |
Why?
| | Phthalazines | 1 | 2021 | 45 | 0.170 |
Why?
| | Heterografts | 1 | 2021 | 138 | 0.170 |
Why?
| | Pheochromocytoma | 1 | 2021 | 59 | 0.170 |
Why?
| | Adrenal Gland Diseases | 1 | 2020 | 6 | 0.170 |
Why?
| | Nuclear Proteins | 1 | 2025 | 712 | 0.170 |
Why?
| | Paraganglioma | 1 | 2021 | 52 | 0.170 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2025 | 801 | 0.160 |
Why?
| | Benzamides | 1 | 2021 | 216 | 0.160 |
Why?
| | Indolizines | 1 | 2019 | 4 | 0.160 |
Why?
| | Signal Transduction | 5 | 2025 | 5079 | 0.160 |
Why?
| | Forkhead Box Protein M1 | 1 | 2019 | 7 | 0.160 |
Why?
| | Immune System | 1 | 2021 | 177 | 0.160 |
Why?
| | Quinoxalines | 1 | 2019 | 66 | 0.150 |
Why?
| | Cell Cycle Checkpoints | 1 | 2019 | 98 | 0.150 |
Why?
| | Estrogens | 1 | 2022 | 367 | 0.150 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 215 | 0.150 |
Why?
| | Pituitary ACTH Hypersecretion | 1 | 2018 | 10 | 0.150 |
Why?
| | Neoplasms, Experimental | 1 | 2019 | 176 | 0.150 |
Why?
| | Gonadal Steroid Hormones | 1 | 2020 | 140 | 0.150 |
Why?
| | Lamin Type B | 1 | 2018 | 7 | 0.150 |
Why?
| | Gadolinium | 1 | 2019 | 82 | 0.150 |
Why?
| | NIMA-Related Kinases | 1 | 2018 | 8 | 0.150 |
Why?
| | Trans-Activators | 1 | 2021 | 398 | 0.150 |
Why?
| | Naphthyridines | 1 | 2018 | 19 | 0.150 |
Why?
| | Aged | 7 | 2025 | 23961 | 0.140 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2020 | 327 | 0.140 |
Why?
| | Protein Kinase Inhibitors | 2 | 2015 | 916 | 0.140 |
Why?
| | Immunoblotting | 1 | 2018 | 308 | 0.140 |
Why?
| | DNA-Binding Proteins | 1 | 2025 | 1502 | 0.140 |
Why?
| | Carcinogenesis | 1 | 2019 | 217 | 0.140 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 210 | 0.140 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 190 | 0.140 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2018 | 346 | 0.140 |
Why?
| | RNA, Small Interfering | 1 | 2019 | 622 | 0.130 |
Why?
| | Microarray Analysis | 1 | 2017 | 117 | 0.130 |
Why?
| | Transcription Factors | 1 | 2025 | 1719 | 0.130 |
Why?
| | Kidney | 1 | 2025 | 1468 | 0.130 |
Why?
| | Mutation | 3 | 2021 | 3958 | 0.130 |
Why?
| | Liver Neoplasms | 1 | 2023 | 786 | 0.130 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 172 | 0.130 |
Why?
| | Mice, Inbred BALB C | 1 | 2020 | 1272 | 0.130 |
Why?
| | Immunohistochemistry | 2 | 2018 | 1738 | 0.130 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2015 | 19 | 0.120 |
Why?
| | Phosphatidylethanolamines | 1 | 2016 | 77 | 0.120 |
Why?
| | Contrast Media | 1 | 2019 | 467 | 0.120 |
Why?
| | Gonadotrophs | 2 | 2015 | 21 | 0.120 |
Why?
| | Male | 11 | 2025 | 67762 | 0.120 |
Why?
| | Colorectal Neoplasms | 1 | 2023 | 806 | 0.120 |
Why?
| | Phosphatidylcholines | 1 | 2016 | 147 | 0.120 |
Why?
| | Phosphorylation | 1 | 2019 | 1759 | 0.110 |
Why?
| | Proto-Oncogene Proteins | 1 | 2018 | 648 | 0.110 |
Why?
| | Testosterone | 2 | 2023 | 409 | 0.110 |
Why?
| | Cell Survival | 4 | 2021 | 1120 | 0.100 |
Why?
| | Young Adult | 3 | 2025 | 13209 | 0.100 |
Why?
| | Prospective Studies | 2 | 2023 | 7604 | 0.090 |
Why?
| | Hypogonadism | 1 | 2012 | 92 | 0.090 |
Why?
| | Veterans | 1 | 2023 | 1476 | 0.090 |
Why?
| | Antigens, Differentiation | 1 | 2011 | 83 | 0.090 |
Why?
| | Models, Molecular | 1 | 2015 | 1570 | 0.080 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 510 | 0.080 |
Why?
| | Glycoproteins | 1 | 2012 | 342 | 0.080 |
Why?
| | Quality of Life | 1 | 2022 | 2892 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 1 | 2011 | 327 | 0.080 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2010 | 212 | 0.070 |
Why?
| | Reproduction | 1 | 2010 | 204 | 0.070 |
Why?
| | Pyrazoles | 1 | 2012 | 423 | 0.070 |
Why?
| | Pyridines | 1 | 2012 | 506 | 0.070 |
Why?
| | Binding Sites | 2 | 2025 | 1303 | 0.070 |
Why?
| | Neoplasm Staging | 1 | 2012 | 1389 | 0.070 |
Why?
| | Insulin Resistance | 1 | 2016 | 1208 | 0.070 |
Why?
| | Models, Biological | 2 | 2012 | 1783 | 0.070 |
Why?
| | Age Factors | 1 | 2014 | 3295 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3566 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2015 | 767 | 0.060 |
Why?
| | Carcinoma, Papillary | 1 | 2006 | 81 | 0.060 |
Why?
| | DNA, Neoplasm | 1 | 2006 | 164 | 0.060 |
Why?
| | Neoplasms | 1 | 2021 | 2671 | 0.060 |
Why?
| | Muscle, Skeletal | 1 | 2016 | 1724 | 0.060 |
Why?
| | Cell Movement | 1 | 2010 | 967 | 0.060 |
Why?
| | Gene Silencing | 1 | 2006 | 195 | 0.060 |
Why?
| | Forkhead Box Protein O3 | 1 | 2025 | 17 | 0.060 |
Why?
| | Transcription Factor Pit-1 | 1 | 2025 | 27 | 0.060 |
Why?
| | p300-CBP Transcription Factors | 1 | 2025 | 26 | 0.060 |
Why?
| | Insulin | 1 | 2016 | 2409 | 0.060 |
Why?
| | Up-Regulation | 2 | 2021 | 843 | 0.060 |
Why?
| | Receptor, Notch1 | 1 | 2025 | 64 | 0.060 |
Why?
| | Protein Binding | 2 | 2025 | 2224 | 0.060 |
Why?
| | Ipilimumab | 1 | 2025 | 33 | 0.060 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2006 | 224 | 0.060 |
Why?
| | CTLA-4 Antigen | 1 | 2025 | 99 | 0.060 |
Why?
| | Exercise | 1 | 2016 | 2057 | 0.050 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2025 | 96 | 0.050 |
Why?
| | Enhancer Elements, Genetic | 1 | 2025 | 190 | 0.050 |
Why?
| | Floxuridine | 1 | 2023 | 5 | 0.050 |
Why?
| | Triamcinolone Acetonide | 1 | 2023 | 28 | 0.050 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 1081 | 0.050 |
Why?
| | United States | 1 | 2020 | 14841 | 0.050 |
Why?
| | Hepatic Artery | 1 | 2023 | 62 | 0.050 |
Why?
| | Databases, Genetic | 1 | 2024 | 237 | 0.050 |
Why?
| | Phosphoproteins | 1 | 2025 | 338 | 0.050 |
Why?
| | HEK293 Cells | 1 | 2025 | 730 | 0.050 |
Why?
| | Thyroid Neoplasms | 1 | 2006 | 343 | 0.050 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2025 | 430 | 0.050 |
Why?
| | RNA, Long Noncoding | 1 | 2024 | 181 | 0.050 |
Why?
| | Stress, Physiological | 2 | 2015 | 443 | 0.050 |
Why?
| | Follicle Stimulating Hormone | 1 | 2023 | 244 | 0.050 |
Why?
| | DNA Methylation | 1 | 2006 | 643 | 0.040 |
Why?
| | Aurora Kinase B | 1 | 2021 | 8 | 0.040 |
Why?
| | Cellular Senescence | 1 | 2023 | 189 | 0.040 |
Why?
| | Neurons | 1 | 2010 | 1590 | 0.040 |
Why?
| | Chimerism | 1 | 2021 | 31 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 87 | 0.040 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 75 | 0.040 |
Why?
| | Precision Medicine | 1 | 2024 | 429 | 0.040 |
Why?
| | Mice, SCID | 1 | 2021 | 367 | 0.040 |
Why?
| | Drug Synergism | 1 | 2021 | 382 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 565 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 601 | 0.040 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2019 | 155 | 0.040 |
Why?
| | Zebrafish | 1 | 2023 | 499 | 0.040 |
Why?
| | Cell Death | 1 | 2020 | 374 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 452 | 0.040 |
Why?
| | MicroRNAs | 1 | 2024 | 692 | 0.040 |
Why?
| | Remission Induction | 1 | 2018 | 288 | 0.040 |
Why?
| | Pilot Projects | 1 | 2023 | 1710 | 0.030 |
Why?
| | Postoperative Period | 1 | 2018 | 342 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1079 | 0.030 |
Why?
| | Cell Line | 2 | 2012 | 2847 | 0.030 |
Why?
| | Molecular Docking Simulation | 1 | 2015 | 114 | 0.030 |
Why?
| | Molecular Conformation | 1 | 2015 | 145 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 622 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2015 | 34 | 0.030 |
Why?
| | Cytoprotection | 1 | 2015 | 56 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2025 | 2691 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2015 | 103 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2016 | 366 | 0.030 |
Why?
| | Gene Amplification | 1 | 2015 | 104 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2015 | 226 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 182 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2021 | 3015 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 283 | 0.030 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 278 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 2016 | 696 | 0.020 |
Why?
| | Aging | 1 | 2023 | 1864 | 0.020 |
Why?
| | Indoles | 1 | 2015 | 412 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 437 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 861 | 0.020 |
Why?
| | Phenotype | 1 | 2021 | 3196 | 0.020 |
Why?
| | G2 Phase | 1 | 2012 | 38 | 0.020 |
Why?
| | Athletes | 1 | 2016 | 423 | 0.020 |
Why?
| | Sulfonamides | 1 | 2015 | 513 | 0.020 |
Why?
| | Lung Neoplasms | 1 | 2025 | 2526 | 0.020 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2012 | 124 | 0.020 |
Why?
| | CpG Islands | 1 | 2012 | 157 | 0.020 |
Why?
| | Cytoplasm | 1 | 2012 | 274 | 0.020 |
Why?
| | Genes, p53 | 1 | 2011 | 72 | 0.020 |
Why?
| | Olfactory Pathways | 1 | 2010 | 36 | 0.020 |
Why?
| | Cell Division | 1 | 2012 | 794 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2012 | 658 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1062 | 0.020 |
Why?
| | Neurogenesis | 1 | 2010 | 149 | 0.020 |
Why?
| | DNA Damage | 1 | 2011 | 420 | 0.020 |
Why?
| | Hypoxia | 1 | 2015 | 1112 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1250 | 0.020 |
Why?
| | Monocarboxylic Acid Transporters | 1 | 2006 | 22 | 0.020 |
Why?
| | Tissue Inhibitor of Metalloproteinase-3 | 1 | 2006 | 9 | 0.020 |
Why?
| | Death-Associated Protein Kinases | 1 | 2006 | 11 | 0.020 |
Why?
| | Receptors, Retinoic Acid | 1 | 2006 | 43 | 0.020 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2006 | 182 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5778 | 0.020 |
Why?
| | Blood Glucose | 1 | 2016 | 2186 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2006 | 188 | 0.020 |
Why?
| | Cation Transport Proteins | 1 | 2006 | 134 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 976 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2018 | 10811 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2531 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2011 | 7635 | 0.010 |
Why?
| | Adolescent | 1 | 2018 | 21513 | 0.010 |
Why?
| | Disease Progression | 1 | 2006 | 2757 | 0.010 |
Why?
|
|
Kiseljak-Vassiliades's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|